Biomarkers and surrogate endpoints in cardiovascular therapeutics research: Under scrutiny following results of the ENHANCE study

Cardiovascular Therapeutics

Volumn 26, Issue 2, 2008, Pages 85-88

  Pauriah, Maheshwar ^a   Struthers, Allan D ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTIMA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; C-REACTIVE PROTEIN; CAROTID ARTERIES; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; REPRODUCIBILITY OF RESULTS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 46749085180     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2008.00048.x     Document Type: Editorial

References (22)

1. AstraZeneca (2008) Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit [press release]. Available at : http://www.astrazeneca.com/pressrelease/5385.aspx accessed 31 March 2008.
2. Biomarkers and surrogate endpoints (2001) Preferred definitions and conceptual framework. Clin Pharmacol Therap 69 : 89 95.
3. Boissel JP, Collet JP, Moleur P, Haugh M (1992) Surrogate endpoints: a basis for rational approach. Eur J Clin Pharmacol 43 : 235 244.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al 2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New Engl J Med 343 : 1520 1528, 1522 p following 1528.
5. Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H (2005) Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6 : 3.
6. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, Marx N (2005) Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25 : 1804 1809.
7. Hiltunen MO, Tuomisto TT, Niemi M, Brasen JH, Rissanen TT, Toronen P, Vajanto I, Yla-Herttuala S (2002) Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis 165 : 23 32.
8. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, et al 2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Eng J Med 358 : 1431 1443.
9. Landmesser U, Hornig B, Drexler H (2004) Endothelial function: A critical determinant in atherosclerosis Circulation 109 : II27 II33.
10. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115 : 459 467.
11. Lowe GD (2002) Hormone replacement therapy: Prothrombotic vs. protective effects. Pathophysiol Haem Thromb 32 : 329 332.
12. Merck (2008) Update on ACHIEVE: A study of Merck's investigational extended-release niacin/laropiprant (Cordaptive) [press release]. Available at http://www.merck.com/newsroom/press_releases/research_and_development/2008_0331. html accessed 31 March 2008.
13. Morrow DA, Braunwald E (2003) Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation 108 : 250 252.
14. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. New Engl J Med 352 : 29 38.
15. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 356 : 2457 2471.
16. Omenn GS (2004) Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis Markers 20 : 131 134.
17. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) C-reactive protein levels and outcomes after statin therapy. New Engl J Med 352 : 20 28.
18. Ridker PM, Danielson E, Rifai N, Glynn RJ (2006) Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 48 : 73 79.
19. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 : 930 934.
20. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 : 948 954.
21. Verma S, Szmitko PE (2003) Coxibs and the endothelium. J Am Coll Cardiol 42 : 1754 1756.
22. Westendorp IC, in 't Veld BA, Bots ML, Akkerhuis JM, Hofman A, Grobbee DE, Witteman JC (1999) Hormone replacement therapy and intima-media thickness of the common carotid artery: The Rotterdam study. Stroke: J Cerebr Circul 30 : 2562 2567.